Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumors 2Neoplasms 2Glioblastoma 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × brigimadlin × Clear all
NCT05372367 2026-02-03

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Boehringer Ingelheim

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumors

NCT05613036 2025-01-22

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Boehringer Ingelheim

Phase 1 Completed
13 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡